Rochelle Gail Scheib, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Salivary Gland Diseases | 1 | 2000 | 37 | 0.180 |
Why?
|
| Breast Neoplasms | 9 | 2025 | 21156 | 0.170 |
Why?
|
| Parotid Gland | 1 | 2000 | 178 | 0.170 |
Why?
|
| AIDS-Related Complex | 3 | 1987 | 107 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 18048 | 0.160 |
Why?
|
| Germ-Line Mutation | 2 | 2024 | 1884 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 6 | 1996 | 2203 | 0.150 |
Why?
|
| Melatonin | 2 | 2014 | 669 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2022 | 968 | 0.140 |
Why?
|
| Cysts | 1 | 2000 | 685 | 0.120 |
Why?
|
| Genotype | 2 | 2025 | 13047 | 0.100 |
Why?
|
| Hot Flashes | 1 | 2014 | 330 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2024 | 3586 | 0.090 |
Why?
|
| Penicillamine | 2 | 1987 | 60 | 0.090 |
Why?
|
| Phenotype | 2 | 2025 | 16712 | 0.080 |
Why?
|
| Metalloproteases | 1 | 2008 | 61 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 3230 | 0.070 |
Why?
|
| Polyribonucleotides | 1 | 1987 | 4 | 0.070 |
Why?
|
| Poly U | 1 | 1987 | 12 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2019 | 2780 | 0.070 |
Why?
|
| Poly I-C | 1 | 1987 | 111 | 0.070 |
Why?
|
| Affect | 1 | 2014 | 1498 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 4906 | 0.060 |
Why?
|
| RNA, Double-Stranded | 1 | 1987 | 292 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1097 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5103 | 0.060 |
Why?
|
| HIV | 3 | 1988 | 1596 | 0.060 |
Why?
|
| Antioxidants | 1 | 2012 | 1678 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 6978 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2022 | 326 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2023 | 592 | 0.040 |
Why?
|
| Liver Failure | 1 | 2001 | 252 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2022 | 518 | 0.040 |
Why?
|
| Homosexuality | 3 | 1987 | 268 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 1985 | 1386 | 0.040 |
Why?
|
| HIV Infections | 2 | 2001 | 17564 | 0.040 |
Why?
|
| Taxoids | 1 | 2000 | 669 | 0.030 |
Why?
|
| HIV-2 | 1 | 1996 | 156 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 624 | 0.030 |
Why?
|
| Neoplasms | 1 | 2025 | 22386 | 0.030 |
Why?
|
| Lithium | 2 | 1988 | 600 | 0.030 |
Why?
|
| Female | 11 | 2025 | 396943 | 0.030 |
Why?
|
| Humans | 20 | 2025 | 768451 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2000 | 1737 | 0.030 |
Why?
|
| Mammography | 1 | 2022 | 2436 | 0.020 |
Why?
|
| Alleles | 1 | 2022 | 6890 | 0.020 |
Why?
|
| Adult | 12 | 2025 | 223542 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2001 | 1594 | 0.020 |
Why?
|
| Cause of Death | 1 | 2001 | 3727 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2012 | 415 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2014 | 12450 | 0.020 |
Why?
|
| Thymosin | 1 | 1987 | 47 | 0.020 |
Why?
|
| Middle Aged | 9 | 2025 | 223418 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2008 | 239 | 0.020 |
Why?
|
| HIV Antigens | 1 | 1987 | 328 | 0.020 |
Why?
|
| Aged | 5 | 2025 | 171520 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2012 | 4041 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2025 | 81834 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 59680 | 0.020 |
Why?
|
| Male | 10 | 2025 | 364781 | 0.020 |
Why?
|
| Postmenopause | 1 | 2014 | 2519 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 635 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3816 | 0.010 |
Why?
|
| Estradiol | 1 | 2012 | 1949 | 0.010 |
Why?
|
| Chlorides | 1 | 1987 | 663 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 1943 | 0.010 |
Why?
|
| Survivors | 1 | 2014 | 2381 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1987 | 992 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2019 | 24311 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 1988 | 510 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 791 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3438 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 988 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 1987 | 1341 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 1988 | 5495 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6242 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1987 | 2865 | 0.010 |
Why?
|
| Monocytes | 1 | 1987 | 2591 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1987 | 3212 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1987 | 10784 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 963 | 0.010 |
Why?
|
| Risk Factors | 2 | 2019 | 74915 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2001 | 2596 | 0.010 |
Why?
|
| Depression | 1 | 2014 | 8235 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 13324 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 2751 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1996 | 925 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 13497 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 60045 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 4861 | 0.010 |
Why?
|
| Viral Load | 1 | 2001 | 3399 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2008 | 7895 | 0.010 |
Why?
|
| Interleukin-2 | 2 | 1988 | 1894 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 89168 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 22293 | 0.010 |
Why?
|
| Brain | 1 | 1996 | 27438 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2000 | 4931 | 0.010 |
Why?
|
| Phylogeny | 1 | 1996 | 2846 | 0.000 |
Why?
|
| Pokeweed Mitogens | 1 | 1987 | 38 | 0.000 |
Why?
|
| Phytohemagglutinins | 1 | 1987 | 165 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1987 | 306 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 6091 | 0.000 |
Why?
|
| Lithium Carbonate | 1 | 1988 | 179 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2014 | 65409 | 0.000 |
Why?
|
| Survival Analysis | 1 | 2000 | 10125 | 0.000 |
Why?
|
| Lithium Chloride | 1 | 1987 | 83 | 0.000 |
Why?
|
| Comorbidity | 1 | 2001 | 10601 | 0.000 |
Why?
|
| Time Factors | 1 | 1987 | 40271 | 0.000 |
Why?
|
| Erythema | 1 | 1986 | 262 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 13452 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1986 | 1629 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1996 | 5152 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 17647 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1987 | 1765 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1986 | 1604 | 0.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1988 | 977 | 0.000 |
Why?
|
| Hospitalization | 1 | 2001 | 10845 | 0.000 |
Why?
|
| Virus Replication | 1 | 1986 | 2459 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1986 | 3472 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1987 | 19041 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1986 | 10273 | 0.000 |
Why?
|